Fineline Cube

Follow:
14433 Articles
CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer
Legal / IP

CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer

Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach
Others

Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach

Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema
CompanyDrug

Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema

Arvinas and Pfizer's Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer
CompanyDrug

Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer

J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants
CompanyMedical Device

J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer
CompanyDrug

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer

Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004
CompanyDeals

Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China
CompanyDeals

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D
CompanyDeals

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D

Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition
Company

Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
CompanyDrug

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma

Junshi Biosciences' Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
CompanyDrug

Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment